Ali A Haydar, Deborah Mukherji, Walid Faraj, Mohammad Khalifeh, Bedros Taslakian, Zeinab Abou Yehia, Sally Temraz, Karen T Brown, Ghassan K Abou-Alfa, Ali Shamseddine
BACKGROUND: The combination of systemic antiangiogenic therapy and transarterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (HCC) is the subject of several ongoing clinical trials. We present a series of patients treated with sorafenib and TACE at our institution, highlighting the technical challenges of combining these two modalities of treatment. METHODS: We retrospectively identified patients with HCC treated with TACE and sorafenib at our institution...
May 2014: Gastrointestinal Cancer Research: GCR